MANY MINDEDMouse Study Shows Growth Hormone Blockade Extends Lifespan
A study published in *Aging Cell* found that mice with growth hormone receptor (GHR) knocked out at 12 months—equivalent to midlife in humans—showed extended lifespans. Female mice lived up to 4 months longer than control mice, while males exhibited reduced body size and lean mass but improved survival curves. Both sexes gained fat mass and lost lean mass later in life, yet maintained normal inflammatory markers and physical strength. Males also showed better insulin response and lower fasting glucose. Liver gene expression shifted significantly, with stronger effects in males. The research suggests pharmacological inhibition of growth hormone signaling during adulthood could promote healthy aging. FDA-approved growth hormone antagonist Pegvisomant exists but has not been tested for lifespan extension in humans.
This work targets a specific aging mechanism: halting growth hormone signaling at midlife. The sex-specific outcomes—improved metabolic health in males despite muscle loss, survival gains in females without weight changes—highlight how aging interventions may vary by biology. For abundance, this pathway could eventually make healthspan extension more accessible if safely translated to humans. Current progress remains preclinical, with no human trials or safety data for aging applications.
Next steps include verifying human applicability and testing Pegvisomant for healthspan effects. The study’s caveats are critical: findings are mouse-only, midlife intervention doesn’t translate directly to humans, and tissue-specific effects require further development before clinical use. Human trials remain untested, and the FDA-approved drug has not been evaluated for lifespan extension.
Source: Lifespan.io